TARA-002(Protara Therapeutics)

N/A

Report date: 2026/05/02 20:00:18

Base Information

Drug NameTARA-002(Protara Therapeutics)
Drug Alias NameTARA-002
ClassificationCell and gene therapy > Cell therapy
Mechanisms of ActionImmunostimulantsToll like receptor 4 agonists
TargetsToll like receptor 4
Therapy Area/IndicationsLymphatic AbnormalitiesUrinary Bladder Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesUkraine +[9] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesProtara Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesProtara Therapeutics IncSyneos Health（Beijing）Inc Ltd
Inactive CompaniesN/A
Active IndicationsLymphatic AbnormalitiesUrinary Bladder Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A